產(chǎn)品描述

等級：活性藥物成分（API）

化學(xué)名稱：4-{3-氯-4-[（環(huán)丙基氨基）氨基]苯氧基}-7-甲氧基-6-喹啉甲酰胺

分子式：C21H19ClN4O4

分子量：426.853

規(guī)范：按照ChP/USP/EP建立企業(yè)標(biāo)準(zhǔn)

外觀:粉

總雜質(zhì)：不大于0.5%

純度：不低于99%

殘留溶劑：完全符合ICH Q3C要求

致突變雜質(zhì)：完全符合ICH M8

亞硝胺評估：可用

粒度：可根據(jù)客戶要求進行普通級或研磨/篩分

儲存方法：室溫

生產(chǎn)能力：商用

標(biāo)準(zhǔn)包裝：1公斤/袋，5公斤/袋或根據(jù)客戶要求

產(chǎn)品用途

Lenvatinib API是一種受體酪氨酸激酶（RTK）抑制劑，可抑制血管內(nèi)皮生長因子（VEGF）受體VEGFR1 （FLT1）、VEGFR2 （KDR）和VEGFR3 （FLT4）的激酶活性。Lenvatinib還抑制其他與致病性血管生成、腫瘤生長和癌癥進展有關(guān)的RTKs，包括成纖維細(xì)胞生長因子（FGF）受體FGFR1、2、3和4；這些位于細(xì)胞膜上的受體酪氨酸激酶（RTKs）在信號轉(zhuǎn)導(dǎo)通路的激活中起著核心作用，這些信號轉(zhuǎn)導(dǎo)通路參與細(xì)胞過程的正常調(diào)節(jié)，如細(xì)胞增殖、遷移、凋亡和分化，以及在致病性血管生成、淋巴生成、腫瘤生長和癌癥進展中。特別是，VEGF已被確定為生理性和病理性血管生成的關(guān)鍵調(diào)節(jié)因子，并且在許多類型的癌癥中，VEGF表達的增加與預(yù)后不良有關(guān)。

Lenvatinib API適用于局部復(fù)發(fā)或轉(zhuǎn)移性進展性放射性碘（RAI）難治性分化甲狀腺癌患者的治療。大多數(shù)甲狀腺癌患者通過手術(shù)和激素治療有很好的預(yù)后（98%的5年生存率）。然而，對于rai難治性甲狀腺癌患者，治療選擇有限，預(yù)后較差，這促使人們推動開發(fā)更有針對性的治療方法，如lenvatinib。

聯(lián)系方式

四川青木制藥有限公司

四川省眉山市東坡區(qū)經(jīng)濟開發(fā)區(qū)東區(qū)順江大道南段55號

國際營銷部(International):

Email: sales@eastonpharma.cn 

Tel: 028-87827187

國內(nèi)營銷部(Mainland)：

李經(jīng)理 13880480517   

楊經(jīng)理 15982276454

Product Description

• Grade: Active Pharmaceutical Ingredient(API)

• Chemical Name: 4-{3-Chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxy-6-quinolinecarboxamide

• Molecular Formula: C21H19ClN4O4

• Molecular Weight: 426.853

• Specification: Enterprise Standard established according to ChP/USP/EP

• Appearance: Powder

• Total impurities: not more than 0.5%

• Purity: not less than 99%

• Residual Solvents: fully comply with ICH Q3C

• Mutagenic impurities: fully comply with ICH M8

• Nitrosamine assessment: available

• Particle size: regular grade or milling/sieving according to customer’s requirement.

• Storage: Room temperature

• Production capacity: Commercial

• Standard Package: 1kg/bag, 5kg/bag or  according to customer’s requirement.

Applications 

• Lenvatinib API is a receptor tyrosine  kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR),  and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been  implicated in pathogenic angiogenesis, tumor growth, and cancer  progression in addition to their normal cellular functions, including  fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation,      migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumor growth, and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and  pathologic angiogenesis and increased expression of VEGF is associated  with a poor prognosis in many types of cancers.

• Lenvatinib API is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5-year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.

Contact Information

Sichuan Qingmu Pharmaceutical Co., Ltd.

Add: No. 55, South Shunjiang Avenue, East Economic Development Zone, Dongpo District, Meishan City, Sichuan, 620036, China

International Marketing Department: 

Email: sales@eastonpharma.cn 

Tel: 0086-28-87827187